Abstract
Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19.
Highlights
Cancer care during COVID-19 pandemic On 11 March 2020, the WHO declared the 2019 novel coronavirus outbreak an international Public Health Emergency [1]
IL-17 promotes the production of G-CSF, IL-6, IL-1b and TNF-α that lead to systemic inflammatory symptoms, including fever
Huang et al have performed comparison between patients who had been admitted to the intensive care unit and those who had not, observing that serum levels of IL2, IL7, IL10,G-CSF, IP10, MCP1, MIP1A and TNF-α are higher in intensive care units patients, suggesting that the cytokine storm is associated with disease severity [8]
Summary
Cancer care during COVID-19 pandemic On 11 March 2020, the WHO declared the 2019 novel coronavirus outbreak an international Public Health Emergency [1]. The immune response induced by COVID-19 is two-phased. When the protective immune response is inadequate, the patient enters the second phase, the severe stage, characterized by strong inflammatory response, massive tissue damage especially in the lung and in organs that have high angiotensin-converting enzyme 2 expression, such as intestine and kidney [4].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
